INCY
Incyte Corp
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
Did you know?
A large-cap company with a $19.3B market cap.
Current Price
$96.91
+1.72%GoodMoat Value
$271.40
180.1% undervaluedProfile
Valuation (TTM)
Market Cap$19.29B
P/E13.47
EV$14.21B
P/B3.73
Shares Out199.01M
P/Sales3.60
Revenue$5.36B
EV/EBITDA8.18
Incyte Corp (INCY) Stock Analysis
GoodMoat Analysis
Incyte Corp is a biotechnology company with a strong financial profile, including high profitability and a robust balance sheet, but its competitive moat appears limited. The stock is priced at a significant discount to GoodMoat's target, suggesting a potentially favourable valuation. A deeper investigation is warranted to assess the durability of its advantages against the risks inherent in biotech.
Read full analysis
Incyte Corp is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology. Its lead product, Jakafi, is a cornerstone of its revenue. Applying the GoodMoat framework, the company's moat score is likely modest, potentially meeting criteria like proprietary technology (patented drugs) and regulatory barriers (FDA approvals), but it faces high disruption risk from new clinical trials and lacks the diversified platform of larger peers. Its quality indicators, however, are strong: an ROE of 24.9% exceeds the 15-20% high-return threshold, operating margin is healthy at 29.5%, the balance sheet is nearly debt-free (Debt/Equity of 0.007), and it boasts a high profit margin of 25.0% with a 27.8% YoY revenue growth. The valuation is compelling, with a P/E of 14.1 and a Free Cash Flow Yield of 7.5%. GoodMoat's target price of $271.40 implies a margin of safety of approximately 194% from the current $92.23, which falls into the 'Deeply Undervalued' band (>40%) per the framework's DCF analysis guidelines. Following the Decision Framework, the strong quality metrics would allow an investor to proceed to valuation analysis, where the massive discount appears highly favourable. However, the assessment is contingent on a deeper understanding of the moat's durability and the typical red flags in biotech, such as patent cliffs and clinical trial risks, which are not fully captured in the provided data.
Market Cap$19.29B
Current Price$96.91
P/E Ratio13.47
Forward P/E—
PEG Ratio0.16
EPS$6.41
Book Value$25.97
P/B Ratio3.73
INCY Financial Charts
INCY 52-Week Range
$58.98
$110.57
50-Day MA: $95.73200-Day MA: $93.49
Did you know?
Profit margin of 26.7% — that's well above average.
Incyte Corp (INCY) Financial Summary
Incyte Corp (INCY) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $96.91 with a market capitalization of $19.29B.
Key valuation metrics include a P/E ratio of 13.47, price-to-book ratio of 3.73, and EPS of $6.41. The company reports a profit margin of 26.7% and return on equity of 27.7%.
INCY Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $19.29B |
| P/E Ratio | 13.47 |
| EPS | $6.41 |
| P/B Ratio | 3.73 |
| P/S Ratio | 3.60 |
| EV/EBITDA | 8.18 |
| Profit Margin | 26.7% |
| Return on Equity | 27.7% |
| Debt/Equity | 0.01 |
Incyte Corp (INCY) Valuation
Based on GoodMoat's DCF model, Incyte Corp has a fair value estimate of $271.40. At the current price of $96.91, the stock appears 64.3% undervalued relative to our intrinsic value estimate.
INCY Quality Indicators
Incyte Corp maintains a profit margin of 26.7% and an operating margin of 29.5%. Return on equity stands at 27.7%. The current ratio is 3.32. Debt-to-equity ratio is 0.01.
About Incyte Corp
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
INCY Free Cash Flow
Incyte Corp generated $1.35B in trailing twelve-month free cash flow, representing an FCF yield of 7.02%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
INCY Shares Outstanding
Incyte Corp has 0.20 billion shares outstanding at a share price of $96.91, giving it a market capitalization of $19.29B.
INCY Recent Insider Trades
Recent insider transactions at Incyte Corp include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| CAGNONI PABLO J (President, Global Head of R&D) | SELL | 18,667 | $1.80M |
| CAGNONI PABLO J (President, R&D) | SELL | 18,668 | $1.88M |
| Issa Mohamed Khairie (EVP, Head of US Oncology) | SELL | 10,856 | $1.18M |